3D Printing in Pharma – 4 years after the first FDA approval: where are we now?  | KN 6781

23.05. - 24.05.2019 | Antwerp, Belgium


Ramada Plaza Antwerp
Desguinlei 94
2018 Antwerp
Tel.:0032 3 244 82 61

Kursprogramm zum Download


3D printing holds the promise of tailor made, highly individual dosage forms, implants and even tissues and organs. Within the last years, printing techniques that were deemed non-applicable were demonstrated to be viable options for pharmaceutical 3D printing and the investigation of quality standards is shifting into focus. Yet, only a limited number of 3D printed products and only one 3D printed medicine are commercially available.


This course is organized for scientists and decision makers from industry and academia who are interested in the possibilities and techniques of 3D printing in a pharmaceutical context. 4 years after the first FDA approval of a 3D printed drug, recent scientific advances and developments will be covered and discussed.

Furthermore, the course covers topics regarding excipient selection, a first-in-human study, the application of
printing technolgies in a hospital setting and regulatory aspects.

Please Notice: Limited places for full time students available; written evidence must be submitted.


Goals of the seminar:

In this seminar, leading minds from academia and industry discuss the current state and potential future developments for pharmaceutical 3D printing. Sessions cover the manufacturing of solid dosage forms, the selection of suitable excipients, technical considerations for printers and material considerations for bioprinting.
Recent achievements but also limitations of printed drug delivery systems are presented and discussed. The seminar ends with a session by speakers about the application of printing technologies in a hospital setting and regulatory aspects of dosage form printing.


Lieven Baert, PhD

Lieven Baert, Ph.D., M.B.A. Managing Director JALIMA PHARMA.

Lieven has studied at the University of Ghent (Belgium) where he has obtained the degrees of Pharmacist, Industrial Pharmacist, Ph.D. in Pharmaceutical Technology and Master in Business and Administration.

After a post doc at Merck Canada, Lieven has worked at Janssen Pharmaceutica for more than 10 years, where he held different positions, such as Manager Clinical Supplies, CM&C leader and Director Formulation group. Thereafter Lieven joined the sister company Tibotec where he became Senior Research Fellow / Vice President Early Development and Innovation.

In 2007, Lieven was awarded the Johnson & Johnsons Philip B. Hoffman award for Scientists for his innovation work on novel dosage forms for anti-viral drugs. Lieven is inventor on 22 patents and is Flanders District of Creativity Fellow. Lieven started his own company “Jalima Pharma” in 2010.

Peter Hölig, PhD

Peter Hölig, PhD has more than 10 years of experience in the pharmaceutical and chemical industry.

At Evonik Nutrition & Care GmbH he is currently responsible for identifying and leading pharmaceutical and medical strategic innovation activities and projects within the Business Line Health Care.

In his previous role at Abbott/AbbVie he was responsible for the formulation and process development - from bench-top up to commercial scale - of commercialized oral and parenteral solid dosage forms including the manufacturing of clinical trial supplies.

He is a pharmacist by training (University of Heidelberg) and received his PhD from the University of Marburg in 2005 (Supervisors: Prof. T. Kissel and Prof. A. Fahr, Thesis: “Generation and Characterization
of Immunoliposomes”, conducted at vectrontherapeutics AG).

Peter Hölig is the author and co-author of several research papers, patents and conference abstracts.

Julian Quodbach, PhD

Julian Quodbach is a pharmacist by training and started his PhD in 2011 at the Institute of Pharmaceutics and Biopharmaceutics at the University of Düsseldorf under the supervision of Prof. Peter Kleinebudde. He received his PhD in 2014 and began his work as postdoc in the group of Prof. Jörg Breitkreutz. He is supervising several PhD and master students who work on the progression of pharmaceutical 3D printing as well as the use of PAT in granulation processes.

In January 2019, he joined the Drug Delivery Group at Uppsala University for a one year postdoc period.

Anne Seidlitz

Anne Seidlitz obtained her license as a pharmacist in 2003.
She worked as a team member and later on team leader in the galenics department of the Arzneimittel Werke Altona AG in Hamburg.

She returned to Greifswald University and received a Doctor of Natural Sciences in Pharmaceutical Technology in 2009. Since then, she has been working as a postdoctoral fellow in the Biopharmaceutics
and Pharmaceutical Technology department of the University of Greifswald.

In 2015 she was granted the degree of a habilitated Doctor in the Natural Sciences. Her main research area are dosage form development with a focus on 3d-printed formulations and also parenteral dosage forms including injections and implants with special emphasis on (bio-)relevant dissolution testing.


Industry 1.490,00 €
Authority / University 745,00 €
Students 178,00 €
Alle Preise mehrwertsteuerfrei gemäß § 4,22 UStG



Dr. Martin Bornhöft
Tel.: +49 6131 9769-0
Fax: +49 6131 9769-69
E-Mail: apv@apv-mainz.de
www: https://www.apv-mainz.de/